Status of Programmed Death Ligand 1 (PD-L1) by Immunohistochemistry and Scoring Algorithms

The detection of the Programmed Death Ligand 1 (PD-L1) protein by immunohistochemistry is currently the only approved test predictive of response to drugs targeting the PD1/PDL1 axis. The role of this test is debated since several reagents have been used as companion diagnostics for different drugs...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Current drug targets Jg. 21; H. 13; S. 1286
Hauptverfasser: Giunchi, Francesca, Gevaert, Thomas, Scarpelli, Marina, Fiorentino, Michelangelo
Format: Journal Article
Sprache:Englisch
Veröffentlicht: United Arab Emirates 01.01.2020
Schlagworte:
PD-L1
algorithms
immunohistochemistry
scoring systems
immunotherapy
Cancer
ISSN:1873-5592, 1873-5592
Online-Zugang:Weitere Angaben
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The detection of the Programmed Death Ligand 1 (PD-L1) protein by immunohistochemistry is currently the only approved test predictive of response to drugs targeting the PD1/PDL1 axis. The role of this test is debated since several reagents have been used as companion diagnostics for different drugs on diverse immunostaining platforms. In addition, different scoring systems for PD-L1 immunohistochemistry have been applied in the registration studies regarding single drugs. This review deals with the various issues that are related to the immunohistochemical test for PD-L1. We discuss currently unsolved problems such as the advantages and the flaws of PD-L1 immunohistochemistry; the choice of the best reagents and the best scoring system. Finally, we review the current experiences on the role of immunohistochemistry for PD-L1 in clinical trials with immune checkpoint inhibitors.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:1873-5592
1873-5592
DOI:10.2174/1389450121666200123124642